Caristo was founded in 2018 by Cardiologists at the University of Oxford, following a decade of scientific research and technical development, and is now a leader in supporting the transformation of healthcare from treatment-based medicine to prevention. Caristo’s technology aims to revolutionise diagnosis and treatment, enabling physicians to identify patients with the highest heart attack risk and prescribe effective, personalised treatments that can prevent a fatal heart attack.
To date the company has raised a total of £10.2 million, they recently closed a successful investment round led by BGF and existing investors including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).
New products in the pipeline will also be capable of predicting stroke and diabetes risk, years in advance.
Business funding insights
BGF explains: Is private equity the best way to fund an M&A growth strategy?
What to consider when seeking private equity funding for acquisitive growth, from investment timelines to deal types and more
BGF explains: what do private equity investors look for in a business?
We explain what private equity investors look for in the businesses they invest in, from your growth plan to your management team.